Now in its 17th year of operation, Dana-Farber/Harvard Cancer Center (DF/HCC) was the first consortium model, NCI-designated Comprehensive Cancer Center in the country. The consortium is comprised of 1,100 members from five principal Harvard-affiliated hospitals and two Harvard health science schools: Beth Israel Deaconess Medical Center (BIDMC), Boston Children's Hospital (BCH, Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Harvard T. H. Chan School of Public Health (HSPH), and Massachusetts General Hospital (MGH). The progress presented in this proposal has required DF/HCC leadership, its combined resources, and, most importantly, its consortium structure. The overarching scientific vision is to unite the members. The research of the Center is carried out in Research Programs that cross both scientific and institutional boundaries. In addition, the Center supports Shared Resources dedicated to enhancing scientific efficiency available to all Center members. The unified clinical research infrastructure has made it easier for members to conduct clinical trials across the Center. Indirect indications of scientific progress are the substantial growth in the Center's grant portfolio, from $233 million in 1999 to $406 million in 2004, to $623 million in 2009, to $683M and the award of multiple translational grants that transcend organizational boundaries (e.g., SPOREs, SCORs, P01s, U01s, and SU2Cs). There is also an array of hypothesis-driven, Early Phase (pilot, I, I-II), and proof-of-concept trials, made possible through the development and execution of the Center, that are conducted daily across the consortium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006516-52
Application #
9208392
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-03-10
Project End
2021-11-30
Budget Start
2016-12-22
Budget End
2017-11-30
Support Year
52
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Mills, Evanna L; Pierce, Kerry A; Jedrychowski, Mark P et al. (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560:102-106
Oser, Matthew G; Fonseca, Raquel; Chakraborty, Abhishek A et al. (2018) Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov :
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351
Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231
Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583

Showing the most recent 10 out of 411 publications